2025 started with a number of large-scale acquisitions in the MedTech sector. Among others, Stryker and Boston Scientific announced deals exceeding USD 1 billion. While the number of transactions is declining, overall deal volume is rising. Healthcare and life sciences companies that complete more than one acquisition per year have generated an average total shareholder return (TSR) of 13.6% over the past decade, compared to just 0.3% for inactive players. Even a limited number of strategic acquisitions (>1 deal/year) has proven beneficial, with an average TSR of 11.5%. The key is not quantity, but the strategic quality of transactions.
Read the full article: MedTech Consolidation: Buy-and-Build Strategies, Post-Merger Integration, and MDR Compliance //
Source: https://www.taylorwessing.com/en/insights-and-events/insights/2025/09/medtech-consolidation-buy-and-build-post-merger-and-mdr-compliance